Chronic heart failure - An epidemic of the 21 st century;Krónikus szívelégtelenség - A 21. Század epidémiája

Orvosi Hetilap

Volumn 146, Issue 20 SUPPL. 2, 2005, Pages 1075-1087

  Czuriga, István ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NONE   (Hungary)

Author keywords

Clinical trials; Heart failure; Medical therapy; Novel therapies

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT; ANGIOTENSIN II; DIGITALIS GLYCOSIDE; ENDOTHELIN RECEPTOR; ERYTHROPOIETIN; IMMUNOLOGIC FACTOR; PEPTIDE HYDROLASE; VASOPRESSIN DERIVATIVE;

ADRENERGIC SYSTEM; ARTIFICIAL HEART PACEMAKER; ASSISTED CIRCULATION; CLINICAL TRIAL; DEFIBRILLATOR; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HEART TRANSPLANTATION; HUMAN; MEDICAL PRACTICE; MORTALITY; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; DRUG EFFECT; HEART ASSIST DEVICE; HOSPITALIZATION; HUNGARY; METHODOLOGY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DEFIBRILLATORS, IMPLANTABLE; DIGITALIS GLYCOSIDES; DIURETICS; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HEART-ASSIST DEVICES; HUMANS; HUNGARY; IMMUNOLOGIC FACTORS; PACEMAKER, ARTIFICIAL; PEPTIDE HYDROLASES; PRIMARY PREVENTION; RECEPTORS, ENDOTHELIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VASOPRESSINS;

EID: 22144461427     PISSN: 00306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Abassi, Z. A., Tate, J. E., Colomb. E. és mtsai: Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992, 20, 89-95.
2. Abdulla, J., Burchardt, H., Abildstrom, Sz. és mtsai: on behalf of TRACE study group. The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function. Eur. Heart. J., 2003, 23, 2116-2122.
3. Abraham, W. T., Fisher, W. G., Smith, A. L. és mtsai: Multicenter InSync randomized clinical evaluation. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med., 2002, 346, 1845-1853.
4. Al Ahmad, A., Rand, W., M., Manjunath, G. és mtsai: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 2001,38, 955-962.
5. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, TX: American Heart Association, 2002.
6. Auricchio, A., Stellbrink, C., Butter, C. és mtsai: Pacing Therapies in Congestive Heart Failure (PATH-CHF) II Study Group. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of left ventricular conduction delay. J. Am. Coll. Cardiol. 2003, 42, 2109-2116.
7. Bardy, G. H., Lee, K. L., Mark, D. B.: Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure. N. Eng. J. Med., 2005, 352, 225-237.
8. Brecker, S. J., Xiao, H. B., Sparrow, J. es misa: Effects of dual chamber pacing with short atrioventricular delay in dilated cardiomyopathy. Lancet, 1992, 340, 1308-1312.
9. Bristow, M. R., Saxon, L. A., Boehmer, J. és misai: Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med., 2004, 350, 2140-2150.
10. Burnett, J., C. Jr.: Vasopeptidase inhibition: A new concept in blood pressure management. J. Hypertens. 1999, 17 (Suppl.), S37-43.
11. Burnier, M.: Angiotensin II type 1 receptor blockers. Circulation 2001, 703, 904-912.
12. Buxton, A. E., Lee, K. L., Fisher, J. D. és mtsai: A randomized study of the prevention of sudden death in patients with coronary artery disease. N. Engl. J. Med., 1999, 341, 1882-1890.
13. Cacoub, P., Dorent, R., Nataf, P. és mtsai: Plasma endothelin and pulmonary pressures in parients with congestive heart failure. Am. Heart. J. 1993, 126, 1484-1488.
14. Cazeau, S., Ledercq, T., Walker, S. és mtsai: Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N. Engl. J. Med., 2001, 344, 873-880.
15. Chugh, A., Knight, B. P.: Biventricular pacing for dilated cardiomyopathy: proper patient selection. Am. Coll. Cardiol. Curr. Journ. Rev., 2002, 11, 77-80.
16. Cody, R., J., Haas, G., J., Binkley, P., F. és mtsai: PLasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992, 85, 504-509.
17. Cohn, J., N., Johnson, G., Ziesche, S. És mtsai: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med., 1991, 325, 303-310.
18. Cohn, J., N., Tognoni, G.: (Valsartan Heart Failure Trial Investigators). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001, 345, 1667-1675.
19. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA 1988, 259, 539-544.
20. Cowie, M. R., Struthers, A. D., Wood, D. A. és mtsai:. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997, 350, 1349-1353.
21. Cowie, M. R., Wood, D. A. Coats, A. J., S. és mtsai: Incidence and etiology of heart failure. Eur. Heart. J., 1999, 20, 421-428.
22. Czuriga I., Dékány M., Édes I. és mtsai: A krónikus szívelégtelenség diagnózisa és kezelése. Kardiológiai Szakmai Kollégium irányelve. In Kardiológiai Útmutató 2. Medition Kiadó, Budapest, 2003, 53-89. old.
23. DiBianco, R., Shabetai, R., Kostuk, W., és mtsai: A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N. Engl. J. Med., 1989, 320, 677-683.
24. Dobbs, S. M., Kenyon, W. I., Dabbs, R. J.: Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. Br. Med. J., 1977, 1, 749-752.
25. Dupuis, J., Goresky, C. A., Fournier, A.: Pulmonary clearance of circulating endothelin-1 in dogs invivo: exclusive role of ETB receptors. J. Appl. Physiol., 1996, 81, 1510-1515.
26. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [published erratum appears in N. Engl. J. Med. 1992, 327, 1768]. N. Engl. J. Med., 1992, 327, 685-691.
27. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med., 1991, 325, 293-302.
28. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HEART FAILURE). Lancet, 1999, 353, 2001-2007.
29. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet, 1993, 342, 821-828.
30. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med., 1987, 316, 1429-1435.
31. Eriksson, H., Svardsudd, K., Larssan, B. és mtsai: Risk factors for heart failure in the general population: the study of men born in 1913. Eur. Heart. J., 1989, 10, 647-656.
32. Ezekowitz, J. A., McAlister, F. A., Armstrong, P. W.: Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003, 107, 223-225.
33. Francis, G. S., Benedict, C., Johnstonen, D. E.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction. Circulation, 1990, 82, 1724-1729.
34. Francis, G. S., Goldsmith, S. R., Levine, T. B.: The neurohumoral axis in congestive heart failure. Ann. Intern. Med. 1984, 101(3), 370-377.
35. Gheorghiade, M., Bonow, R. O.: Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation, 1999, 97, 282-289.
36. Gheorghiade, M., Gattis, W. A., O'Connor, C. M.: Treatment gaps in the pharma-cological management of heart failure. Rev. Cardiovasc. Med., 2002, 3, S11-S19.
37. Gottlieb, S. S., Dickstein, K., Fleck, E. és mtsai: Hemodynamic and neurohormonal effects of the angiotensin II antagonist in patients with congestive heart failure. Circulation, 1993, 88, 1602-1609.
38. Granger, C. B., McMurray, J. J. V., Yusuf, S. és mtsai: for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003, 362, 772-776.
39. Gregoratos, G., Abrams, J., Epstein, A. E. és mtsai: ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J. Am. Coll. Cardiol., 2002, 40, 1703-1719.
40. Guidelines for the diagnosis and treatment of chronic heart failure. Task Force for the Diagnosis and Treatment of Chronic Heart Failure. European Society of Cardiology: Remme, W. J., Swedberg, K. Eur. Heart. J., 2001, 22, 1527-1560.
41. Gullestad, L., Aass, H., Fjeld, J. G.: Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation, 2001, 103, 220-225.
42. Haldeman, G. A., Croft, J. B., Giles, W. H. és mtsai: Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am. Heart. J., 1999, 137, 352-360.
43. Hauer, R. N., Aliot, E., Block, M. és mtsai: European Society of Cardiology. Working Group on Arrhythmias and Working Group on Cardiac Pacing: Indications for implantable cardioverter defibrillator (ICD) therapy. Study Group on Guidelines on ICDs of the Working Group on Arrhythmias and the Working Group on Cardiac Pacing of the European Society of Cardiology. Eur. Heart J., 2001, 22, 1074-1781.
44. Hensen, J., Abraham, W. T., Durr. J. A. és mtsai: Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am. J. Nephrol., 1991, 11, 441-446.
45. Higgins, S. L., Hummel, J. D., Niazi, I. K. és mtsai: Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J. Am. Coll. Cardiol., 2003, 42, 1454-1459.
46. Ho, K. K. L., Pinsky, J. L., Kannel, W. B. és mtsai: The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. 1993, 22 (Suppl. A), 6A-13A.
47. Horwich, T. B., Fonarow, G. C., Hamilton, M. A. és mtsai: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J. Am Coll. Cardiol., 2002, 39, 1780-1786.
48. Hunt, S. A., Baker, D. W., Chin, M. H. és mtsai: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J. Am. Coll. Cardiol., 2001, 38, 2101-2113.
49. Jelliffe, R. W., Brooker, G.: A nomogram for digoxin therapy. Am. J. Med., 1974, 57, 63-68.
50. Jong, Ph., Yusuf, S., Rousseau, M. és mtsai: Effect of enalapril on 12-years survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet, 2003, 361, 1843-1848.
51. Kadish, A., Dyer, A., Daubert, J. P. és mtsai: Prophylactic defibrillator implantation in patients with nonischaemic dilated cardiomyopathy. N. Engl. J. Med., 2004, 350, 2151-2158.
52. Kalra, P. R., Moon, J. C, Coats, A. J. és mtsai: Do results of the Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol., 2002, 55, 195-197.
53. Kober, L., Torp-Pedersen, C., Carlsen, J. E. és mtsai: for the Trandolapril Cardiac Evaluation (TRACE) Study Group. Effects on mortality by trandolapril after myocardial infarction. N. Engl. J. Med., 1995, 333, 1670-1676.
54. Komuro, I., Kurihara, H., Sugiyama, T. és mtsai: Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS. Lett., 1988, 238, 249-252.
55. Lee, D. C., Johnson, R. A., Bingham, J. B. És mtsai: Heart failure in outpatients: a randomized trial of digoxin versus placebo. N. Engl. J. Med., 1982, 306, 699-705.
56. Maggioni, A. P., Anand, I., Gottlieb, S., O. és mtsai: Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: Valsartan Heart Failure Trial (Val-HeFT). Circulation., 2002, 40, 1414-1421.
57. Malek, M.: Health economics of heart failure. Heart. 1999, 82. IV11-IV13.
58. Mancini, D. M., Katz, S. D., Lang, C. C. és mtsai: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation, 2003, 107, 294-299.
59. Mann, D. for the RENEWAL Investigators: Effects of etanercept on the morbidity and mortality in patients with chronic heart failure: results of the Randomized Etanercept World-Wide Evaluation (RENEWAL) Study. Presented at the Heart Failure Update Meeting, June 8-11, 2002, Oslo, Norway.
60. Margulies, K. B., Hildebrand, F. L. Jr., Lerman, A. és mtsai: Increased endothelin-1 in experimental heart failure. Circulation., 1990, 82, 2226-2230.
61. Matthew, J., Sleight, P., Lonn, E. és mtsai: for the Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation, 2001, 104, 1615-1621.
62. McKee, P. A., Castelli, W. P., McNamara, P. M. és mtsai: The natural history of congestive heart failure: the Framingham study. N. Engl. J. Med., 1971, 285, 1441-1446.
63. McMurray, J. J.. Ray, S. G., Abdullah, I. és mtsai: Plasma endothelin in chronic heart failure. Circulation, 1992, 85, 1374-1379.
64. McMurray, J. J., V., Östergren, J., Swedberg, K. és mtsai: for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet, 2003, 362, 767-771.
65. Miller, L. W., Missov, E. D.: Epidemiology of heart failure. Cardiol. Clin., 2001, 19, 547-555.
66. Moss, A. J., Hall, W. J., Cannom, D. S. és mtsai: Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N. Engl. J. Med., 1996, 335, 1933-1940.
67. Moss, A. J., Zareba, W., Hall, W. J. és mtsai: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med., 2002, 46, 877-883.
68. O'Connell, J. B., Bristow, M. R.: Economic impact of heart failure in the United States: time for a different approach. J. Heart Lung Transplant., 1994, 13, S107-S112.
69. Oseroff, O., Retyk, E., Bochoeyer, A.: Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH). Curr. Opin. Cardiol., 2003, 19, 26-30.
70. Packer, M., Bristow, M. R., Cohn, J. N. és mtsai: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med., 1996, 334, 1349-1355.
71. Packer, M., Califf, R. M., Konstam, M. A. és mtsai.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation, 2002, 106, 920-926.
72. Packer, M., Caspi, A., Charlon, V. és mtsai: Multicenter, doubleblind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure-results of the REACH-I trial. Circulation, 1998, 98 (Suppl.), 1-3.
73. Packer, M. for the ATTACH Investigators: Effects of anti-TNF-_ therapy against chronic heart failure. Presented at the Heart Failure Update Meeting, June 8-11, 2002, Oslo, Norway.
74. Packer, M., Gheorghiade, M., Young, J. B. és mtsai: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N. Engl. J. Med., 1993, 329, 1-7.
75. Packer, M., Fowler, M., Roecker, E. És mtsai: for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Effect of Carvedilol on Morbidity of Patients with Severe Chronic Heart Failure. Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation, 2002, 106, 2194-2199.
76. Parker, J., O.: The effects of oral ibopamine in patients with mild heart failure - a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int. J. Cardiol. 1993, 40, 221-227.
77. Peifley, K. A., Winkles, J. A.: Angiotensin II and endothelin-1 increase fibroblast growth factor-2 mRNA expression in vascular smooth muscle cells. Biochem. Biophys. Res. Comm., 1988, 242, 202-208.
78. Pfeffer, M. A., Braunwald, E., Moye, L. A. és mtsai: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med., 1992, 327, 669-677.
79. Pfeffer, M. A., Braunwald, E., Moye, L. A. és mtsai: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med., 1992, 327, 669-677.
80. Pfeffer, M. A., Swedberg, K., Granger, C. B. és mtsai: for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362, 759-765.
81. Pitt, B., Poole-Wilson, P. A., Segal, R. és mtsai: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet, 2000, 355, 1582-1587.
82. Pitt, B., Remme, W., Zannad, F. és mtsai: for the Eplerenone Post Acut Myocardial Infarction Heart Failure Efficacy and Survival Study Investigation. Eplerenone, a Selective Aldosterone Blocker, in Patients with left Ventricular Dysfunction after Myocardial Infarction. N. Engl. J. Med., 2003, 34S, 1309-1321.
83. Pitt, B., Zannad, F., Remme, W. J. és mtsai: The effect of spironolattone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med., 1999, 347, 709-717.
84. Poole-Wilson, P. A., Swedberg, K., Cleland, J. G. F. és mtsai: for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003, 362, 7-13.
85. Press release, European Society of Cardiology XXIV Congress, Berlin, 2002.
86. Priori, S. G., Aliot, E., Blomstrom-Lundqvist, C. és mtsai: Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur. Heart J., 2001, 22, 1374-1450.
87. Priori, S. G., Allot, E., Blomstrom-Lundqvist, C.: European Society of Cardiology: Update of the guidelines on sudden cardiac death of the European Society of Cardiology. Eur. Heart J., 2003, 24, 13-15.
88. Rademaker, M. T., Charles, C. J., Espiner, E. A. és mtsai: Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II. J. Cardiovasc. Pharmacol., 1998, 31, 116-125.
89. Rathore, S. S., Curtis, J. P., Wang, Y., Bristow, M. R. és mtsai: Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA, 2003, 289, 871-878.
90. Rauchhaus, M., Doehner, W., Francis, D. P. és mtsai: Plasmacytokine parameters and mortality in patients with chronic heart failure. Circulation, 2000, 102, 3060-3067.
91. Richardson, A., Bayliss, J., Scriven, A. J. és mtsai: Double-blind comparison of captopril alone against furosemide plus amiloride in mild heart failure. Lancet, 1987, 2, 709-711.
92. Rodeheffer, R. J., Lerman, A., Heublein, D. M. és mtsai: Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clinic Proc., 1992, 67, 719-24.
93. Rouleau, J. L., Pfeffer, M. A., Stewart, D. J. és mtsai: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet, 2000, 356, 615-620.
94. Seed, A., Hillier, C., Berry, C. és mtsai: Evidence that a novel orally active NEP/ECE inhibitor blocks the vasoconstrictor response to big endothelin in human resistance arteries. J. Am. Coll. Cardiol., 2001, 37 (Suppl. A), 237A.
95. Seta, Y., Shan, K., Bozkurt, és mtsai: Basic mechanisms in heart failure: Cytokine hypothesis. J. Card. Fail., 1996, 3, 243-249.
96. Silverberg, D. S., Wexler, D., Blum, M. és mtsai: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol., 2000, 35, 1737-1744.
97. Skudicky, D., Bergemann, A., Sliwa, K. és mtsai: Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Circulation., 2001, 103, 1083-1088.
98. Struthers, A. D.: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J. Card. Fail., 1996, 2, 47-54.
99. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet, 1999, 353, 9-13.
100. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N. Engl. J. Med. 1997, 336, 525-533.
101. Torre-Amione, G., Bozkurt, B., Deswal, A. és mtsai: An overview of tumor necrosis factor alpha and the failing human heart. Curr. Opin. Cardiol., 1999, 14, 206-210.
102. Uretsky, B. E, Young, J. B., Shahidi, F. E. és mtsai: Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J. Am. Coll. Cardiol., 1993, 2, 955-962.
103. van der Meer, P., Voors, A. A., Lipsic, E. és mtsai: Erythropoietin in cardiovascular diseases. Eur. Heart. J. 2004, 25, 285-291.
104. Volpe, M., Tritto, C., Testa, U. és mtsai: Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am. J. Cardiol., 1994, 74, 468-473.
105. Weber, K. T., Villarreal, D.: Aldosterone and antialdosterone therapy in congestive heart failure. Am. J. Cardiol., 1993, 71, 3A-11A.
106. Wei, C. M., Lerman, A., Rodeheffer, R. J. és mtsai: Endothelin in human congestive heart failure. Circulation, 1994, 89, 1580-1586.
107. Willenheimer, R., Erdmann, E., Follath, F. és mtsai: Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. Eu J Heart Failure, 2004, 6, 493-500.
108. Wilson, J. R., Reichek, N., Dunkman, W. B. és mtsai: Effect of diuresis on the performance of the failing left ventricle in man. Am. J. Med., 1981, 70, 234-239.
109. Young, J. B., Abraham, W. T., Smith, A. L. és mtsai: Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. J. Am. Med. Assoc., 2003, 289, 2685-2694.
110. Yusuf, S., Pfeffer, M. A., Swedberg, K. és mtsai: CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet, 2003, 362, 777-781.
111. Zabalgoitia, M., Berning, J., Koren, M. J. és mtsai: for the LIFE Study Investigators. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (The LIFE Study). Am. J. Cardiol., 2001, 88, 646-650.
112. Zannad. F. Aldosterone and heart failure. Eur. Heart. J. 1995, 16 (Supplements N), 98-102.